On March 19, 2024, Fusion Pharmaceuticals announced that it entered into a definitive agreement to be acquired by AstraZeneca for a transaction value of approximately US$2.4 billion.
Through this acquisition, AstraZeneca is taking a significant leap towards its goal of revolutionizing cancer treatment and patient outcomes by substituting traditional methods such as chemotherapy and radiotherapy with more directed treatments.
Fusion Pharmaceuticals operates a clinical-stage oncology company that is focused on developing next-generation radioconjugates.
AstraZeneca is a global, science-led biopharmaceutical business.
Osler, Hoskin & Harcourt LLP advised Fusion Pharmaceuticals with a team consisting of Alex Gorka, Brett Anderson, Chad Bayne, Amy Sigurdson, Shira Dveris (Corporate), David Davachi, Taylor Cao, Matt Zvan (Tax), Lynne Lacoursiere and Nick Guadagnolo (Executive Compensation), Shuli Rodal and Alysha Pannu (Competition/Antitrust and Foreign Investment), Susan Newell, John Greiss (Health), Steven Dickie (Employment), Alison Hayman (Intellectual Property).